Skip Navigation


NDT Advance Access originally published online on July 5, 2007
Nephrology Dialysis Transplantation 2007 22(10):2778-2780; doi:10.1093/ndt/gfm259
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/10/2778    most recent
gfm259v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ostendorf, T.
Right arrow Articles by Floege, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ostendorf, T.
Right arrow Articles by Floege, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Renal side effects of anti-VEGF therapy in man: a new test system*

Tammo Ostendorf1, An S. De Vriese2 and Jürgen Floege1

1Division of Nephrology, RWTH University of Aachen, Aachen, Germany and 2The Renal Unit, AZ Sint-Jan AV, Brugge, Belgium

Correspondence and offprint requests to: Dr Tammo Ostendorf, Division of Nephrology, University Hospital Aachen, Pauwelsstr. 30, D-52057 Aachen, Germany. Email: tostendorf@ukaachen.de

The first 10% of the full text of this article appears below.

Humanized, anti-vascular endothelial growth factor (VEGF) antibodies like bevacizumab (Avastin) have been approved by the FDA for systemic treatment in cancer and local application in age-related macular degeneration [1]. In a recent review and meta-analysis of published clinical trials with bevacizumab, a dose-dependent increase in the risk for proteinuria and hypertension was documented [2]. The FDA therefore issued warnings concerning the renal toxicity and thromboembolic events (http://www.fda.gov/cder/drug/InfoSheets/patient/bevacizumabPIS.htm). Preclinical testing of anti-human VEGF agents in the past was often difficult, since most of the anti-human VEGF antibodies failed to neutralize rodent VEGF-A.



   Summary of key findings
 
In the 27 . . . [Full Text of this Article]



   Background
 


   Take-home-messages
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?